Cargando…

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors

Introduction: A high proportion of metastatic melanoma patients do not respond to immune checkpoint inhibitors (ICI), and until now, no validated biomarkers for response and survival have been known. Methods: We performed a retrospective analysis of outcomes in patients with metastatic melanoma trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mesti, Tanja, Grašič Kuhar, Cvetka, Ocvirk, Janja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044937/ https://www.ncbi.nlm.nih.gov/pubmed/36979727 http://dx.doi.org/10.3390/biomedicines11030749

Ejemplares similares

Molecular Biomarkers and Histological Parameters Impact on Survival and Response to First- Line Systemic Therapy of Metastatic Colorectal Cancer Patients
por: Rebersek, Martina, et al.
Publicado: (2019)

Digital ischemic events related to gemcitabine: Report of two cases and a systematic review
por: Kuhar, Cvetka Grasic, et al.
Publicado: (2010)

Adverse Events During Immunotherapy in Slovenian Patients with Metastatic Melanoma Reveal a Positive Correlation with Better Treatment Outcomes
por: Mesti, Tanja, et al.
Publicado: (2021)

The Five-year KRAS, NRAS and BRAF Analysis Results and Treatment Patterns in Daily Clinical Practice in Slovenia in 1(st) Line Treatment of Metastatic Colorectal (mCRC) Patients with RAS Wild-type Tumour (wtRAS) – A Real- Life Data Report 2013–2018
por: Mesti, Tanja, et al.
Publicado: (2023)

Malignant gliomas: old and new systemic treatment approaches
por: Mesti, Tanja, et al.
Publicado: (2016)

Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience
por: Hribernik, Nezka, et al.
Publicado: (2020)

The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
por: Erman, Ana, et al.
Publicado: (2023)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022)

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement
por: Mesti, Tanja, et al.
Publicado: (2015)

Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer
por: Grašič Kuhar, Cvetka, et al.
Publicado: (2023)

Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report
por: Grasic Kuhar, Cvetka, et al.
Publicado: (2014)

Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer: A case report
por: Besic, Nikola, et al.
Publicado: (2021)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer
por: Kuhar, Cvetka Grašič, et al.
Publicado: (2023)

Effectiveness of adjuvant trastuzumab in daily clinical practice
por: Matos, Erika, et al.
Publicado: (2014)

The Biology and Clinical Potential of Circulating Tumor Cells
por: Lozar, Taja, et al.
Publicado: (2019)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
por: Ocvirk, Janja, et al.
Publicado: (2016)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report
por: Kiraly, Peter, et al.
Publicado: (2022)

Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population
por: Grasic Kuhar, Cvetka, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma
por: Miceska, Simona, et al.
Publicado: (2023)

Morphological Features of Breast Cancer Circulating Tumor Cells in Blood After Physical and Biological Type of Isolation
por: Jesenko, Tanja, et al.
Publicado: (2021)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Mobile App for Symptom Management and Associated Quality of Life During Systemic Treatment in Early Stage Breast Cancer: Nonrandomized Controlled Prospective Cohort Study
por: Grašič Kuhar, Cvetka, et al.
Publicado: (2020)

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
por: Rivas, Alexia, et al.
Publicado: (2022)

Metabolic Impact of Anti-Angiogenic Agents on U87 Glioma Cells
por: Mesti, Tanja, et al.
Publicado: (2014)

Preclinical and Clinical Evaluation of Magnetic-Activated Cell Separation Technology for CTC Isolation in Breast Cancer
por: Lozar, Taja, et al.
Publicado: (2020)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Neuroendocrine Carcinoma of the Larynx and Pharynx: A Clinical and Histopathological Study
por: Strojan, Primož, et al.
Publicado: (2021)

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
por: Carbone, Maria Luigia, et al.
Publicado: (2022)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
por: Wheeler, Caroline E., et al.
Publicado: (2023)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
por: Sivapiragasam, Abirami, et al.
Publicado: (2020)

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gthv52u2skuqa8do9aj82s0boh